换一批Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
第一作者：
Devalingam,Mahalingam
第一单位：
Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, Mahalingam@uthscsa.edu.
作者：
医学主题词
血管生成抑制剂(Angiogenesis Inhibitors);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);疾病恶化(Disease Progression);药物监测(Drug Monitoring);临床试验早期终止(Early Termination of Clinical Trials);可行性研究(Feasibility Studies);女(雌)性(Female);人类(Humans);高血压(Hypertension);动力学(Kinetics);男(雄)性(Male);黑色素瘤(Melanoma);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);烟酰胺(Niacinamide);苯脲化合物(Phenylurea Compounds);蛋白激酶抑制剂(Protein Kinase Inhibitors);受体, 血管内皮生长因子(Receptors, Vascular Endothelial Growth Factor);疾病严重程度指数(Severity of Illness Index);血管内皮生长因子类(Vascular Endothelial Growth Factors)
DOI
10.1007/s00280-014-2479-8
PMID
24817603
发布时间
2018-12-02
- 浏览5
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
